Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Response to FDA Request of Oct 2, 2007- Cervavix, October 4, 2007

From: Edward.M.Yuhas@gsk.com
To: Gemignani, Helen S;
Subject: Cervavix; Response to FDA Request of Oct 2, 2007
Date: Thursday, October 04, 2007 11:09:12 AM
Attachments: HPV-009 request firewall_2Oct07.doc


Helen, At Matt Whitman's request, I am sending you a table that indicates the treatment assignments for the nine patients identified in your request of October 2, 2007. Please note that in the attached table the treatment the patients received was identified as either MPL or Non-MPL. MPL is equivalent to the term HPV and Non-MPL is equivalent to the term HAV. Please note that we will also submit this information to FDA in a 'formal' submission shortly. If you have any questions, I can be reached at 215-751-3836 Regards
"EMF <fda.hhs.gov>" made the following annotations.
------------------------------------------------------------------------------
This message was sent by GlaxoSmith Kline across the Internet in encrypted format and was successfully decrypted, unless otherwise noted. Glaxo Wellcome
============================================

Page Last Updated: 04/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.